See more : Atlas Cycles (Haryana) Limited (ATLASCYCLE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Taysha Gene Therapies, Inc. (TSHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Taysha Gene Therapies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tianjin Development Holdings Limited (TJSCF) Income Statement Analysis – Financial Results
- CoCreation Grass Co., Ltd (605099.SS) Income Statement Analysis – Financial Results
- Belysse Group NV (BALTA.BR) Income Statement Analysis – Financial Results
- Canada One Mining Corp. (ANGUF) Income Statement Analysis – Financial Results
- Yin He Holdings Limited (8260.HK) Income Statement Analysis – Financial Results
Taysha Gene Therapies, Inc. (TSHA)
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 15.45M | 2.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 2.49M | 492.00K | 9.00K | 0.00 |
| Gross Profit | 15.45M | 15.00K | -492.00K | -9.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.60% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.78M | 91.17M | 131.94M | 31.89M | 987.00K |
| General & Administrative | 30.05M | 37.36M | 41.32M | 11.11M | 512.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -384.00K |
| SG&A | 30.05M | 37.36M | 41.32M | 11.11M | 128.00K |
| Other Expenses | 1.07M | -18.00K | 0.00 | -17.03M | 0.00 |
| Operating Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Cost & Expenses | 87.89M | 128.53M | 173.27M | 43.00M | 1.12M |
| Interest Income | 3.57M | 249.00K | 172.00K | 49.00K | 0.00 |
| Interest Expense | 5.00M | 3.80M | 1.43M | 28.00K | 0.00 |
| Depreciation & Amortization | 1.37M | 2.49M | 492.00K | 9.00K | 4.46M |
| EBITDA | -105.20M | -159.73M | -172.78M | -42.99M | 0.00 |
| EBITDA Ratio | -680.84% | -5,027.82% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.44M | -162.45M | -173.27M | -43.00M | -1.12M |
| Operating Income Ratio | -468.83% | -6,492.69% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -39.13M | -3.57M | -1.26M | -17.01M | 0.00 |
| Income Before Tax | -111.57M | -166.01M | -174.52M | -60.01M | -1.12M |
| Income Before Tax Ratio | -722.06% | -6,635.25% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.57M | 936.00K | -17.01M | -4.46M |
| Net Income | -111.57M | -169.58M | -175.46M | -43.00M | -1.12M |
| Net Income Ratio | -722.06% | -6,777.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| EPS Diluted | -0.96 | -3.86 | -4.66 | -2.43 | -0.03 |
| Weighted Avg Shares Out | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
| Weighted Avg Shares Out (Dil) | 116.12M | 43.95M | 37.65M | 17.67M | 36.99M |
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-tolerated with no treatment-emergent SAEs as of 35-week assessment, with sustained improvement across key efficacy measures at decreased steroid levels and...
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today...
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
REVEAL adolescent and adult trial will proceed to high dose cohort following Independent Data Monitoring Committee approval of Company's request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in Q2 2024
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced...
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not...
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced...
3 Growth Stocks That Could Go Parabolic in 2024
Small- to mid-cap growth stocks largely struggled over the past two years. With the Federal Reserve likely to pivot on interest rates this year, this group may be poised for a trend reversal.
Source: https://incomestatements.info
Category: Stock Reports